Solubility based mechanistic profiling of combinatorial drug therapy
Open Access
- 25 March 2026
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 2744
Abstract
Acute myeloid leukemia (AML) remains challenging to treat due to extensive genetic heterogeneity, high relapse rates, and treatment-related toxicity. Although drug combinations offer therapeutic promise, their selection is often empirical. Here, we introduce Combinatorial Proteome Integral Solubility/Stability Alteration analysis (CoPISA), a high-throughput proteomics workflow that captures protein solubility/stability alterations uniquely induced by drug combinations. We applied CoPISA to two rationally designed AML drug pairs, LY3009120-sapanisertib (LS) and ruxolitinib-ulixertinib (RU), previously identified as the most effective and least toxic combinations among many candidates and validated in AML cell lines, patient-derived samples and zebrafish xenograft models. We uncovered an emergent mechanism termed “conjunctional targeting”, in which combinatorial drug action induces combination-exclusive protein targets consistent with an AND-gate logic model. LS-specific converged on SUMOylation, chromatin condensation, and VEGF-linked adhesion, while RU-specific targets disrupted DNA-damage checkpoints, mitochondrial bioenergetics, and RNA-splicing. Post-translational modification analysis revealed combination-induced acetylation, methylation, and phosphorylation of key AML proteins, including NPM1. Network analysis demonstrated that a substantial fraction of AML-associated proteins targeted by CoPISA are unique to combinations, including DNMT3A, NPM1, and TP53. By uncovering a mechanistic layer beyond classical synergy, CoPISA provides a robust framework for the precision-guided design of combinatorial therapies in heterogeneous cancers.Keywords
All Related Versions
Funding Information
- Research Council of Finland (332454)
- Jane ja Aatos Erkon Säätiö (220031)
- Sigrid Juséliuksen Säätiö
- Syöpäsäätiö (4709178)
- Cancerfonden (243595 Pj)
- Vetenskapsrådet (2023-02692)
- Jeanssons Stiftelser (J2023-0094)
This publication has 79 references indexed in Scilit:
- Monitoring Functional Posttranslational Modifications Using a Data‐Driven Proteome Informatic PipelineProteomics, 2025
- Multifaceted Proteome Analysis at Solubility, Redox, and Expression Dimensions for Target IdentificationAdvanced Science, 2024
- Oxidative stress is two‐sided in the treatment of acute myeloid leukemiaCancer Medicine, 2024
- Update on Small Molecule Targeted Therapies for Acute Myeloid LeukemiaCurrent Treatment Options in Oncology, 2023
- 3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?Current Oncology Reports, 2021
- The role of TP53 in acute myeloid leukemia: Challenges and opportunitiesGenes, Chromosomes and Cancer, 2019
- Methods for High-throughput Drug Combination Screening and Synergy Scoring2018
- Multiple testing corrections in quantitative proteomics: A useful but blunt toolProteomics, 2016
- An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug–drug and drug–herb interaction by LC‐ESI/MS/MSBiomedical Chromatography, 2016
- Akute myeloische LeukämieDie Innere Medizin, 2015